将优化新冠疫苗接种方案带给免疫功能低下人群(BOOST-IC):一项适应性随机对照临床试验的研究方案
BOOST-IC是一项在澳大利亚开展的适应性随机试验,针对HIV感染者、实体器官移植受者及血液系统恶性肿瘤患者,评估间隔3个月接种1剂或2剂新冠疫苗加强针的免疫原性与安全性。主要结局为末剂研究疫苗后28天抗刺突SARS-CoV-2 IgG几何平均浓度。
要点
- 纳入已接种3至7剂澳大利亚治疗用品管理局(TGA)批准的新冠疫苗且至少间隔3个月者。
- 排除接种研究疫苗前3个月内接受过SARS-CoV-2特异性单克隆抗体者。
- 主要结局为末剂后28天抗刺突SARS-CoV-2 IgG几何平均浓度。
核心结论
- 本研究将增进对免疫功能低下人群新冠疫苗应答的理解,并有助于为HIV感染者、实体器官移植受者或血液系统恶性肿瘤患者制定安全且优化的疫苗接种方案。
研究设计与样本
- BOOST-IC是一项适应性随机试验,在澳大利亚开展,比较间隔3个月接种1剂或2剂新冠疫苗加强针。
- 研究对象为HIV感染者、实体器官移植(SOT)受者或血液系统恶性肿瘤患者(慢性淋巴细胞白血病、非霍奇金淋巴瘤或多发性骨髓瘤)。
- 关键纳入标准为至少3个月前已接种3至7剂澳大利亚治疗用品管理局(TGA)批准的新冠疫苗,且接种研究疫苗前3个月内未接受过SARS-CoV-2特异性单克隆抗体。
主要发现
- 主要结局为末剂研究疫苗后28天抗刺突SARS-CoV-2免疫球蛋白G(IgG)的几何平均浓度。
- 关键次要结局包括研究疫苗后6个月和12个月抗刺突SARS-CoV-2 IgG滴度及血清阳转比例。
- 关键次要结局还包括接种后7天内局部和全身反应、特殊关注不良事件、COVID-19感染、死亡率和生活质量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunocompromised hosts (ICH) experience more breakthrough infections and worse clinical outcomes following infection with COVID-19 than immunocompetent people. Prophylactic monoclonal antibody therapies can be challenging to access, and escape variants emerge rapidly. Immunity conferred through vaccination remains a central prevention strategy for COVID-19. COVID-19 vaccines do not elicit optimal immunity in ICH but boosting, through additional doses of vaccine improves humoral and cellular immune responses. This trial aims to assess the immunogenicity and safety of different COVID-19 vaccine booster strategies against SARS-CoV-2 for ICH in Australia. METHODS: Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC) is an adaptive randomised trial of one or two additional doses of COVID-19 vaccines 3 months apart in people living with HIV, solid organ transplant (SOT) recipients, or those who have haematological malignancies (chronic lymphocytic leukaemia, non-Hodgkin lymphoma or multiple myeloma). Key eligibility criteria include having received 3 to 7 doses of Australian Therapeutic Goods Administration (TGA)-approved COVID-19 vaccines at least 3 months earlier, and having not received SARS-CoV-2-specific monoclonal antibodies in the 3 months prior to receiving the study vaccine. The primary outcome is the geometric mean concentration of anti-spike SARS-CoV-2 immunoglobulin G (IgG) 28 days after the final dose of the study vaccine. Key secondary outcomes include anti-spike SARS-CoV-2 IgG titres and the proportion of people seroconverting 6 and 12 months after study vaccines, local and systemic reactions in the 7 days after vaccination, adverse events of special interest, COVID-19 infection, mortality and quality of life. DISCUSSION: This study will enhance the understanding of COVID-19 vaccine responses in ICH, and enable the development of safe, and optimised vaccine schedules in people with HIV, SOT, or haematological malignancy. TRIAL REGISTRATION: ClinicalTrials.gov NCT05556720. Registered on 23rd August 2022.
引用
- Griffin DWJ, Dymock M, Wong G, et al. Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial. Trials. 2024. PMID: 39020446. doi:10.1186/s13063-024-08315-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。